Orlando Guntinas-Lichius1,2,3, Jovanna Thielker1,2, K Thomas Robbins4, Kerry D Olsen5, Ashok R Shaha6, Antti A Mäkitie7,8,9, Remco de Bree10, Vincent Vander Poorten3,11, Miquel Quer3,12, Alessandra Rinaldo13, Luiz Paulo Kowalski14, Juan Pablo Rodrigo15, Marc Hamoir16, Alfio Ferlito17. 1. Department of Otorhinolaryngology, Jena University Hospital, Friedrich Schiller University, Jena, Germany. 2. Facial Nerve Center, Jena University Hospital, Friedrich Schiller University, Jena, Germany. 3. Multidisciplinary Salivary Gland Society, Geneva, Switzerland. 4. Department of Otolaryngology-Head and Neck Surgery, Southern Illinois University, Springfield, Illinois, USA. 5. Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota, USA. 6. Head and Neck Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 7. Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 8. Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. 9. Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute and Karolinska Hospital, Stockholm, Sweden. 10. Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. 11. Otorhinolaryngology-Head and Neck Surgery, University Hospitals Leuven and Department of Oncology, Section Head and Neck Oncology, Leuven, Belgium. 12. Department of Otolaryngology, Hospital Santa Creu i Sant Pau, Barcelona, Spain. 13. University of Udine School of Medicine, Udine, Italy. 14. Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center, and Division of Head and Neck Surgery, Sao Paulo State University Medical School, São Paulo, Brazil. 15. Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain. 16. Department of Head & Neck Surgery, St Luc University Hospital and King Albert II Cancer Institute, Brussels, Belgium; Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium. 17. Coordinator of the International Head and Neck Scientific Group, Padua, Italy.
Abstract
BACKGROUND: The prognostic importance of intraparotid lymph node metastasis (P+) in patients with primary parotid gland carcinoma is unclear. METHODS: Nineteen retrospective and noncomparative cohort studies, published between 1992 and 2020, met the inclusion criteria and included 2202 patients for this systematic review. RESULTS: The pooled prevalence of the P in adult patients in the unselected studies was 24.10% (95% confidence interval = 17.95-30.25). The number of P+ lymph nodes per patient was counted in only three studies and ranged from 1 to 11. The 5-year recurrence-free survival rate based on Kaplan-Meier analysis varied from 83% to 88% in P- patients compared to 36% to 54% in P+ patients. The average hazard ratio for tumor recurrence in patients with P+ compared to P- was 2.67 ± 0.58. CONCLUSIONS: P+ is an independent negative prognostic factor in primary parotid gland cancer and should be included into the treatment planning.
BACKGROUND: The prognostic importance of intraparotid lymph node metastasis (P+) in patients with primary parotid gland carcinoma is unclear. METHODS: Nineteen retrospective and noncomparative cohort studies, published between 1992 and 2020, met the inclusion criteria and included 2202 patients for this systematic review. RESULTS: The pooled prevalence of the P in adult patients in the unselected studies was 24.10% (95% confidence interval = 17.95-30.25). The number of P+ lymph nodes per patient was counted in only three studies and ranged from 1 to 11. The 5-year recurrence-free survival rate based on Kaplan-Meier analysis varied from 83% to 88% in P- patients compared to 36% to 54% in P+ patients. The average hazard ratio for tumor recurrence in patients with P+ compared to P- was 2.67 ± 0.58. CONCLUSIONS: P+ is an independent negative prognostic factor in primary parotid gland cancer and should be included into the treatment planning.
Authors: Mussab Kouka; Benjamin Koehler; Jens Buentzel; Holger Kaftan; Daniel Boeger; Andreas H Mueller; Andrea Wittig; Stefan Schultze-Mosgau; Thomas Ernst; Peter Schlattmann; Orlando Guntinas-Lichius Journal: Cancers (Basel) Date: 2022-06-07 Impact factor: 6.575
Authors: Cesare Piazza; Marta Filauro; Frederik G Dikkers; S A Reza Nouraei; Kishore Sandu; Christian Sittel; Milan R Amin; Guillermo Campos; Hans E Eckel; Giorgio Peretti Journal: Eur Arch Otorhinolaryngol Date: 2020-06-06 Impact factor: 2.503
Authors: Konstantinos Mantsopoulos; Zacharias Bessas; Matti Sievert; Sarina Katrin Müller; Michael Koch; Abbas Agaimy; Heinrich Iro Journal: J Clin Med Date: 2022-02-25 Impact factor: 4.241